34 C
Vientiane
Friday, April 25, 2025
spot_img
Home Blog Page 684

The 7th “HK Digital Advertising Start-ups X Publishing (Writers) Promotion Support Scheme”

Unveiling 12 Selected Teams of Local Digital Advertising Start-ups & Emerging Writers

HONG KONG, Jan. 22, 2025 /PRNewswire/ — The Hong Kong Digital Advertising Start-ups X Publishing (Writers) Promotion Support Scheme (the “Support Scheme”), organized by Hong Kong Association of Interactive Marketing (“HKAIM”), and supported by the Cultural and Creative Industries Development Agency (“CCIDA”) of the Government of the Hong Kong Special Administrative Region (“HKSAR Government”) as the lead sponsor, has been nurturing local digital advertising start-ups since its inception in 2018. By providing funding and professional training, the Support Scheme enables these start-ups to design bespoke digital advertising campaigns for local emerging writers, promoting their designated works. The initiative fosters cross-sectoral collaboration between emerging writers, the publishing industry, and the digital advertising industry, creating more opportunities for growth and development.

Guests of Honor took a group photo with the selection committee members, judges, mentors, 12 groups of selected emerging writers and publishers, and representatives of 12 selected local digital advertising start-ups to conclude the Launch Ceremony.
Guests of Honor took a group photo with the selection committee members, judges, mentors, 12 groups of selected emerging writers and publishers, and representatives of 12 selected local digital advertising start-ups to conclude the Launch Ceremony.

Entering its 7th edition, the Support Scheme received overwhelming response to its call for applications which was closed in late 2024, with 50 digital advertising start-ups and 21 emerging writers. The HKAIM has selected among the applicants and paired up 12 teams, each comprises a digital advertising start-up and an emerging writer. The designated books of applied emerging writers cover a wide range of topics, including education, sports, spirituality, history, music, counseling, science, workplace, comics, picture books, and more. The diversity would stimulate more creativities from the digital advertising start-ups as they plan the related campaigns.

The HKAIM successfully kicked off the 7th Support Scheme with a Launch Ceremony at Seminar Hall, Xiqu Centre on 20 January. Mr. Alex So, Head (Multi-media) of CCIDA, was invited to be the Guest of Honor. Along with him, Chairman of the HKAIM Mr. Francis Fong and Vice Chairman of Hong Kong Publishing Federation Mr. William So launched this year’s Support Scheme by announcing the 12 participating teams. (Full list below)

Each digital advertising start-up will receive a subsidy of up to HK$260,000 to design, plan and execute a digital advertising campaign for the designated book of the matched emerging writer. In addition, the HKAIM will provide training by industry experts, helping them to improve the creative concept and execution of their digital advertising campaigns. The Support Scheme not only creates an opportunity for the digital advertising and publishing industries to collaborate, it also promotes Chinese books through viral digital campaigns and cultivates a more robust reading culture.

In addition, the HKAIM will promote the participating digital advertising startups and emerging writers along with the selected books through a wide range of promotion channels including the Support Scheme’s official website, internet, social media, etc. For the 11 digital advertising projects created under last year’s (the 6th) Support Scheme, the campaigns reached nearly 19.56 million people, with nearly 1.33 million engagements, and almost 7.38 million views, successfully bringing attention to the selected books by the emerging writers, and delivering accurate messages from the books to the target audience, creating more opportunities for readers and emerging writers to interact and communicate. The HKAIM is optimistic that this year’s Support Scheme will achieve similarly stellar results.

The HKAIM will also host a booth at Hong Kong Book Fair 2025 in July to showcase the 12 digital advertising campaigns and the designated books. The Digital Advertising Design (for Publishing) Awards Competition and Presentation Ceremony will also be scheduled to recognize the best digital advertising campaign among the 12 as determined by industry experts. The “My Favourite Digital Advertising (for Publishing) Award” based on public voting, will also be presented at the ceremony. The Presentation Ceremony will highlight digital advertising campaigns as well as recognize the efforts of the participating teams.

The HKAIM will post regular updates about the Support Scheme and the 12 teams on our official website and Facebook page. For more details about the Support Scheme, please visit:

Official website: www.digiad.hk
Facebook page: www.facebook.com/AdxPub
Instagram page: www.instagram.com/adxpub_hk

Organizer: The Hong Kong Association of Interactive Marketing
Lead Sponsor: The Cultural and Creative Industries Development Agency of the Government of the Hong Kong Special Administrative Region

Disclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee.

The 12 selected pairs of digital advertising start-ups and emerging writers for the 7th Support Scheme are listed in alphabetical order (according to Start-up) as follows:

Local Digital Advertising Start-up (ENG)

Local Digital Advertising Start-up (CHI)

Publisher

Local New and Emerging Writers (English Name)

Designated Book (Chinese Title)

Designated Book (English Title, if any)

1

At This Moment

n/a

Breakthrough Limited

Wing Yuek Ching

鐡人1.5

One Half

2

FROM THE TOP PRODUCTION LIMITED

優本製作有限公司

Boaz International Education Institute Limited

Chan Cheuk Ki Twiggy,

Shum Yin Wah

我不是笨笨

n/a

3

Gain Tune International Limited

德通國際有限公司

SYRT Academy Company Limited

Yu Wing Kong, Steve

招募之RD

Recruit to RD

4

Hungerr Universe Limited

哼嘎制作有限公司

Ming’s Readers Publisher

Lai Wai Hang,

Li Lo

MBTI人際探險——不同性格類型一起生活,要如何相處?

n/a

5

Kangaroll Creative

n/a

HKEJ Publishing Limited

Cheung Ching Fung

港人防災必修科

n/a

6

Moisland

無島

City University of Hong Kong Press

Lin Ka Chun

被遺忘的香港管樂史

The Forgotten History of Wind Bands in Hong Kong

7

Nine Nine Digital

n/a

Sun Ya Publications (HK) Limited

Leung Tim

未來科學拯救隊3:碧月薄荷大謎團

Future Science Rescue Team (3): The Great Mystery of Green Lunar Mint

8

PI Consultancy & Training Company Limited

n/a

Enrich Publishing Limited

Miss Heart

校園療心室2——自主情緒‧實現真我

n/a

9

Ripple Vision

漣漪映畫

Quire Limited

Cheung Yu Ting (Ar Yu)

靈魂中轉站

SOULTOPIA

10

Storeroom No.9

玖號士多房

Lokrazy Plus Design

Kwan Wai Lok

(Nalok.lok)

可以給我/你一次機會嗎?

One Chance? One Chance.

11

Studio120

120工作室

Chinese Christian Literature Council Ltd

Cheung Ka Yan

神在野——香港山野靈思之旅

God in the wild: Awakening Spirituality in the nature of Hong Kong

12

Tinysotiny.co Limited

n/a

Cosmos Books Limited

Tsang, Mo-suet Musette Faye

的的撐撐開飯啦

n/a

 

PCX Markets Earns B Corp Certification

SINGAPORE, Jan. 22, 2025 /PRNewswire/ — PCX Markets, a marketplace for audited, traceable plastic waste recovery and responsible processing, today announced that it has been certified as a B Corporation™ (B Corp™), further recognizing the company’s commitment to environmental and social responsibility.

PCX Markets Earns B Corp Certification
PCX Markets Earns B Corp Certification

B Corp is a global movement of over 9,400 pioneering companies across 105 countries that use business as a force for good, and includes trailblazers like Ben & Jerry’s, Patagonia, Allbirds, and Coursera.

To become a B Corp company, PCX Markets underwent a rigorous assessment of every part of the business against five key impact areas: governance, workers, community, environment, and customers. Achieving B Corp Certification by the non-profit B Lab reaffirms PCX Market’s deep commitment to transparency and accountability.

“The team at PCX is on mission to accelerate the transition to a circular economy, and build a future where no plastic waste ends up in nature. We are proud to have achieved B Corp certification, and incredibly excited to join this global movement of purpose-driven businesses,” said Sebastian DiGrande, PCX Markets CEO. 

The world has produced about 9 billion metric tons of plastic since the 1950s. Today, only 9% of plastic waste is recycled, 19% incinerated, and 72% is either landfilled, dumped, openly burned or ends up in the environment. Even if we were to reduce production from today’s levels by 40% by 2050, the world would still produce another 11 billion tons that needs to be responsibly managed.

PCX Markets activates an ecosystem of partners who collect, transport and responsibly process plastic waste, while supporting the communities most impacted by the global plastic waste crisis with programs that improve livelihoods and scale social impact. Companies that want to complement upstream reduction efforts by funding downstream plastic waste recovery can purchase credits issued by projects battling plastic pollution. One credit cleans up one metric ton of plastic pollution. The impact is delivered immediately and verified by a third-party auditor.

PCX Markets, which is headquartered in Singapore, has enabled the clean up of over 108 million kilograms of plastic waste worldwide to date.

“As a B Corp in the sustainability sector, we’re thrilled to be counted among businesses that are building an inclusive, equitable, and regenerative economy,” said Nanette Medved-Po, Founder of PCX Markets.

ABOUT PCX

PCX is on a mission to accelerate the transition to a circular economy and build a future where no plastic ends up in nature. 

PCX Markets is a fully transparent plastic credit marketplace for audited, traceable plastic waste recovery and responsible processing worldwide. Our marketplace activates an ecosystem of partners who collect, transport and responsibly process plastic waste, while supporting communities on the ground with programs that improve livelihoods and scale social impact. PCX Markets, which is headquartered in Singapore, has enabled the clean up of over 108  million kilograms of plastic waste worldwide.

About B Lab

B Lab is transforming the global economy to benefit all people, communities and the planet. A leader in economic systems change, our global network creates standards, policies, tools, and programs for business, and we certify companies – known as B Corps – who are leading the way. To date, our community includes over 900,000 workers in over 9,400 B Corps across 105 countries and 160 industries. The B Impact Assessment is used by more than 150,000 companies to help measure, manage and improve their impact. To learn more and join the movement, visit www.bcorporation.net.

About Certified B Corporations™

Certified B Corporations, or B Corps™, are companies verified by B Lab to meet the high standards of social and environmental performance, transparency and accountability.

For press enquiries, contact marketing@pcxmarkets.com

Airport City Blueprint Presented to Business Community with New Brand “SKYTOPIA”


HONG KONG SAR – Media OutReach Newswire – 22 January 2025 – Airport Authority Hong Kong (AAHK) presented the Airport City blueprint to the business community at a major event today as the new brand of the development, “SKYTOPIA”, was unveiled.

Airport City Blueprint Presented to Business Community with New Brand "SKYTOPIA"
Airport City Blueprint Presented to Business Community with New Brand “SKYTOPIA”

The event showcased the development potential and investment opportunities at “SKYTOPIA”, with themed exhibition zones introducing the major projects, attracting over 300 business leaders from Hong Kong, Mainland and international business community.

Integrating commercial activities, popular culture, art trading, entertainment and leisure, “SKYTOPIA” features projects that capitalise the unique advantages of Hong Kong and leverage the land and marine resources near Hong Kong International Airport (HKIA). Highlights include:

  • Hong Kong’s first one-stop art hub which puts art creation, appreciation and trading under one roof;
  • Hong Kong’s first dedicated stand-alone art storage facility;
  • Airport Bay Marina as Hong Kong’s largest yacht bay providing over 500 berths;
  • Hong Kong’s largest water recreation area;
  • Jet Fresh Market with fresh gourmet products delivered from around the globe;
  • Phase 2 development of AsiaWorld-Expo comprising Hong Kong’s largest indoor purpose-built performance venue housing 20,000 spectators;
  • Sportainment complex combining indoor and outdoor sports concepts for adventure, exploration, sports and entertainment;
  • Marine resort and luxury hotel;
  • Promenade encompassing a 1.5 km-long CoveWalk and Piazza;
  • Green and smart transport system featuring automated car parks and autonomous vehicles and more.
Fred Lam, Chairman of AAHK, remarked at the event, “We envisage that HKIA will not be just a place for passengers to board their flights or a portal for entering Hong Kong. Our vision is to develop ‘SKYTOPIA’ into a landmark of its own, and a world-leading destination, attracting visitors from within Hong Kong and the prosperous Greater Bay Area, as well as major markets in Asia and the rest of the world. AAHK’s role is to build the key infrastructure and create a platform for experts and investors to deliver services and products through their specially designed facilities. We are grateful to the HKSAR Government for the policy support and excited to see the positive responses from the business community. We look forward to working with investors to make ‘SKYTOPIA’ a key economic driver of Hong Kong and beyond.”

“SKYTOPIA” embodies the key attributes and aspirations of the development, with “SKY” and “IA” (International Airport) manifesting its airport lineage and global reach, while “TOP” promises top-tier experiences for visitors and highlighting its position as a leading regional landmark. SKYTOPIA is set to be visitors’ dream destination with sky-high attractions.

Hashtag: #HKIA #AirportAuthorityHongKong

The issuer is solely responsible for the content of this announcement.

Hyundai ADM Unveils a “New Paradigm in Cancer Treatment” – Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ — Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the “Biotech Showcase 2025” held in San Francisco from January 13 to 15. The company introduced a “new paradigm in cancer treatment,” shifting from intravenous chemotherapy to patient-centered oral chemotherapy.

Technological Innovation: OTX-M Based on Organic-Inorganic Hybrid Drug Delivery Technology

OTX-M was developed using the patented organic-inorganic hybrid oral drug delivery technology of Hyundai ADM’s affiliated company, CNPharm. Unlike other oral anti-cancer drugs that failed to address drug-drug interaction issues, OTX-M enhances the bioavailability of docetaxel by more than 1,600 times without relying on metabolic inhibitors such as P-gp inhibitors or ritonavir. This breakthrough effectively resolves the challenge of low bioavailability while eliminating concerns about drug interactions.

Preclinical Study Results Identify the Optimal Regimen as One Daily Dose at a Moderate Dosage

The preclinical study systematically evaluated the effects of varying dosages (low, moderate, and high) and dosing frequencies, assessing anti-tumor efficacy and safety, as measured by weight changes.

Low doses administered twice daily showed a tumor inhibition rate of 61.4%, with minimal side effects and stable weight maintenance.

Moderate doses administered once daily achieved a tumor inhibition rate of 82.83%, demonstrating the best balance between anti-tumor efficacy and weight stability.

High doses administered four times per week achieved the highest tumor inhibition rate of 92.81%. However, weight loss and increased risk of side effects made this approach unsuitable for long-term cancer treatment.

The study demonstrated the dose-dependent anti-tumor efficacy of OTX-M, highlighting its excellent safety profile and low risk of side effects. A comprehensive analysis determined that a once-daily moderate dosage offers the optimal balance between efficacy and safety.

The Potential of OTX-M in the Global Cancer Treatment Market

OTX-M is expected to provide greater patient convenience and economic advantages, with the potential to rapidly replacing the current market dominated by injectable chemotherapy drugs. Research by Rutgers University and Chung-Ang University suggests that oral anti-cancer therapies can reduce treatment costs by 59.9% compared to injectable chemotherapies. This cost-effectiveness makes them an ideal solution for underdeveloped regions with limited medical resources. Additionally, the ability for patients to self-administer the medication at home, without the need for hospital visits, provides significant benefits for both patients and healthcare systems.

Global Industry Experts Highlight OTX-M’s Paradigm-Shifting Potential

A lead researcher from the new drug development division of a global pharmaceutical company, attending the Biotech Showcase commented, “The transition of taxane-based drugs, such as docetaxel and paclitaxel, into oral formulations has been a long-standing challenge that many pharmaceutical companies have attempted but failed to overcome. OTX-M represents the first example of successfully addressing both bioavailability and safety concerns. This technology could be a game-changer for cancer treatment and is expected to establish itself as an oral anti-cancer therapy in the global market following clinical trials in the United States.”

Hyundai ADM’s Commitment to Innovation in Cancer Treatment

Hyundai ADM’s CEO, Taek-Sung Kim, stated, “OTX-M is an innovative treatment that converts intravenous chemotherapy drugs into oral therapies with lowered side effects, significantly improving patient convenience and quality of life. We aim to usher in an era where cancer can be managed as a chronic condition, like diabetes or hypertension, and play a leading role in the global anti-cancer market.”

About Hyundai ADM Bio and Hyundai Bioscience

Hyundai ADM Bio is a subsidiary of Hyundai Bioscience, is a biotechnology company that develops anticancer drugs and also a Clinical Research Organization (CRO) service company in South Korea. ADM Korea Inc. is listed on the KOSDAQ market (symbol: 187660).

Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea.

Yuan Zhong Siu Launches New Products, Unlocking Good Luck this Chinese New Year


SINGAPORE – Media OutReach Newswire – 22 January 2025 – As 2025 approaches, Yuan Zhong Siu introduces its latest product collection, combining traditional wisdom with modern solutions. Featuring the 2025 Zodiac Bracelets and Tai Sui Safety Talismans, these products are thoughtfully designed to align with the year’s zodiac forecast, helping individuals enhance their luck, overcome challenges, and achieve balance in the upcoming year.

Crystal Bracelet & Tai Sui Safety Talisman
Crystal Bracelet & Tai Sui Safety Talisman

New Products Aligned with Zodiac Forecast Recommendations
Yuan Zhong Siu’s new product range is tailored to complement the zodiac recommendations, providing personalized support for career growth, relationship harmony, wealth enhancement, and protection against misfortune.

Chinese Zodiac Forecast 2025
The Chinese Zodiac forecast for 2025 reveals a year filled with opportunities and challenges, depending on each zodiac sign’s alignment with the year’s energies. Yuan Zhong Siu’s expert geomancers recommend specific strategies and tools to help each sign navigate the year ahead.

For more detailed zodiac forecast, visit https://yuanzhongsiu.com/zodiac-forecast/

2025 Zodiac Bracelets: Crystals for Luck and Balance
Each Zodiac Bracelet is crafted with natural crystals selected to address specific areas of life based on the zodiac forecast:

  • Wealth and Prosperity: Recommended for signs like the Goat, Dog, and Dragon, the Vegas Bracelet and Arthur the King Bracelet can amplify financial opportunities and sustain wealth luck in 2025.
  • Relationship Growth: Signs facing challenges in relationships, such as the Rabbit and Horse, can benefit from the Galaxy Bracelet, designed to enhance communication and emotional understanding.
  • Healing and Protection: The Ethereal Bracelet is ideal for those encountering obstacles in 2025, such as the Tiger, Snake, and Monkey, providing balance and shielding against misfortune.
  • Personal Growth: For individuals like the Rooster and Ox, who seek growth in career or personal life, the Dynasty Bracelet and Destiny Bracelet inspire self-discovery and goal achievement.


Tai Sui Safety Talisman: Protection Against Misfortune
For individuals born under zodiac signs clashing with Tai Sui in 2025 (Tiger, Snake, Monkey, and Pig), recommends carrying the Tai Sui Safety Talisman. This talisman is designed to mitigate effects of the Tai Sui clash, reduce obstacles and alleviate mental stress. It also supports both personal and professional development, while offering protection from potential misfortune. By carrying this talisman, individuals can pave the way for a luckier Chinese New Year and a successful 2025.

With Chinese New Year approaching, Yuan Zhong Siu is offering limited-time offers for these products. Visit their website here .

Hashtag: #crystalbracelet #safetytalisman #zodiacforecast2025 #yuanzhongsiu





The issuer is solely responsible for the content of this announcement.

About Yuan Zhong Siu

Yuan Zhong Siu, founded by Master Hillary Phang in 1989, offers Feng Shui products and services across Asia. The brand combines traditional Feng Shui principles with modern consultancy to help individuals address life’s challenges. Yuan Zhong Siu provides a range of products aimed at enhancing well-being, career, and financial growth. With retail outlets and offices in Singapore, the brand supports customers seeking solutions through Feng Shui practices.

ROHM’s Second-generation MUS-IC (TM) Series Audio DAC Chip for Hi-res Audio Playback with Exclusive HD Monaural Mode

– Delivers Authentic Listening Experience by Expressing Three Elements of Spatial Reverberation, Quietness, and Dynamic Range While Preserving Natural “Texture” of Musical Instruments –

KYOTO, Japan, Jan. 22, 2025 /PRNewswire/ — ROHM has developed a 32-bit D/A converter IC (DAC chip) and an evaluation board for flagship models in its MUS-IC (TM) series, optimized for high-resolution audio playback. DAC chips are key to audio equipment quality. With over 50 years of expertise, ROHM ensures superior sound design through high-fidelity processors and premium audio power ICs.

Product video: https://youtu.be/5VnsX4SSRQY?si=t_n5OzxBmLpliYZb

ROHM’s latest product builds upon the first-generation MUS-IC (TM) BD34301EKV, renowned for its sound quality and adoption in high-end models. The BD34302EKV inherits the core design concept behind ROHM’s DAC chip, which emphasizes natural flat sound. By integrating the three elements of spatial reverberation, quietness, and dynamic range from the MUS-IC (TM) series, it authentically reproduces the “texture” of musical instruments for an even more realistic audio experience.

Image: https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202501092652/_prw_PI1fl_39cYfY1W.jpg

By incorporating a new algorithm for data-weighted averaging (DWA), the BD34302EKV achieves a THD+N characteristic of -117dB (THD: -127dB), a key performance indicator that enhances sound quality by achieving a sound quality that conveys a realistic sense of texture. In addition, the signal-to-noise ratio (SNR) of 130dB provides noise performance befitting a flagship DAC chip, while a sampling frequency of up to 1,536kHz allows customers to fully leverage the high-precision calculations of their digital signal processors (DSPs).

Product image: https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202501092652/_prw_PI4fl_vtl1N22C.jpg

In monaural mode, which allocates one DAC chip per channel, ROHM’s proprietary HD (high definition) monaural mode contributes to smoother, more natural sound. As part of the MUS-IC (TM) series, uncompromising craftsmanship has been applied down to the smallest details. Based on years of expertise in sound quality design, the optimal bonding wire material for each terminal of the BD34302EKV was selected to accurately convey the natural “texture” of musical instruments. These features help create the ideal sound sought by high-end audio manufacturers.

Special page: https://micro.rohm.com/en/mus-ic/

*In this release, “DAC chip” differentiates the IC from the DAC in audio equipment.

*MUS-IC is a trademark or registered trademark of ROHM Co., Ltd.

Release: https://www.rohm.com/news-detail?news-title=2025-01-22_news_music&defaultGroupId=false

About ROHM: https://kyodonewsprwire.jp/attach/202501092652-O1-39CK07wm.pdf

Logo: https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202501092652/_prw_PI3fl_o748borj.jpg

Official website: https://www.rohm.com/

Automation Anywhere’s AI Agents Power PwC India’s Intelligent Spend Management Suite (ISMS)

DAVOS, Switzerland, Jan. 22, 2025 /PRNewswire/ — Automation Anywhere Inc.(AAI), the world’s leading Agentic Process Automation (APA) platform, and PwC India strengthened their partnership by integrating advanced Agentic AI capabilities from Automation Anywhere into PwC India’s proprietary Intelligent Spend Management Suite (ISMS).

PwC India’s Intelligent Spend Management Suite (ISMS) is an Agentic AI platform designed to transform the way businesses manage their spend and run their payable operations. This product leverages the power of  Generative AI agents which will now be powered by Automation Anywhere. This will give ISMS specific capabilities to drive intelligent buying decisions, execute touchless account payables and enhance critical outcomes.

This modular, Agentic AI platform allows API integrations with existing systems to greatly improve operational efficiency, transparency and insights for better decisions. 

In 2024, Automation Anywhere announced a strategic partnership with PwC India to develop Generative AI-driven solutions aimed at transforming key business operations. The integration of Automation Anywhere’s advanced Agentic AI capabilities into PwC India’s Intelligent Spend Management Suite (ISMS) marks a significant milestone in the collaboration.  

Commenting on the announcement with Automation Anywhere, Sanjeev Krishan, Chairperson, PwC in India said, “The integration of Automation Anywhere’s advanced Agentic AI capabilities into PwC India’s Intelligent Spend Management Suite represents a step forward in addressing some of the most pressing challenges faced by businesses today. By combining our deep industry insights, AI & Tech expertise and domain understanding with Automation Anywhere’s Agentic AI platform, we are empowering organizations across sectors to drive efficiency, enhance decision-making, and unlock greater value in their spend and payable operations.”

Joe Atkinson, PwC’s Global Chief AI Officer added, “Agentic AI is a step-change in the AI revolution, one that is going to play a significant role in the business model reinvention of enterprises globally. AI is starting to disrupt value chains across whole industries, and with ISMS value realization for businesses becomes real. I’m excited to see the collaboration between us and Automation Anywhere.”

“Our industry-leading Agentic Process Automation platform has the unparalleled ability to drive actions by solving real world customer problems with GenAI. We recognize PwC India’s market potential that will significantly increase the deployment of AI Agents aiding in a strategic long-term vision to deliver superior business outcomes for our customers,” said Ankur Kothari, Chief Operating Officer, Automation Anywhere.

Manpreet Singh Ahuja, Chief Digital Officer and Partner, PwC India said, “PwC India’s Intelligent Spend Management Suite which leverages Agentic AI, is an example of our commitment to move AI from experimentation to enterprise grade deployments. This product addresses a key business challenge: making payables management smarter and more efficient. Working with Automation anywhere, we will be able bring collective expertise of both enterprises to solve client challenges.”

Key features of PwC India’s Intelligent Spend Management Suite (ISMS) include:

  • Generative AI agents for advanced process insights, validation and executing actions
  • Modular design for seamless integration with existing systems
  • API-first architecture for faster implementation and scalability
  • Strong underlying layer of data, validations, and workflow implementations

The combined efforts of Automation Anywhere with PwC India is poised to develop breakthrough solutions that will revolutionize the way of working across several business verticals.

About Automation Anywhere Inc

Automation Anywhere is the world’s leading Agentic Process Automation (APA) Platform that puts AI to work across organizations. The company’s platform is powered with specialized AI, generative AI and offers process discovery, RPA, AI agents, end-to-end process orchestration, document processing and analytics, with a security and governance-first approach. Automation Anywhere empowers organizations worldwide to unleash productivity gains, improve customer experiences and create new revenue streams. The company is guided by its vision to fuel the future of work by unleashing human potential through Agentic AI-powered automation. Learn more at www.automationanywhere.com

About PwC

At PwC, our purpose is to build trust in society and solve important problems. We’re a network of firms in 152 countries with over 327,000 people who are committed to delivering quality in Assurance, Advisory and Tax services. Find out more and tell us what matters to you by visiting us at www.pwc.com.

PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.

Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East

DUBAI, UAE , Jan. 21, 2025 /PRNewswire/ — Anbio Biotechnology (“Anbio”), a global leader in in-vitro diagnostic technologies, is excited to announce its participation in the 2025 Medlab Middle East exhibition, taking place from 3rd to 6th February at the Dubai World Trade Centre. The event is one of the region’s largest and most important medical and laboratory equipment trade shows, bringing together leading manufacturers, distributors, and healthcare professionals from around the globe.

Anbio Biotechnology's booth Z1.H50 at 2025 Medlab Middle East
Anbio Biotechnology’s booth Z1.H50 at 2025 Medlab Middle East

Anbio Biotechnology will be showcasing a range of its latest Point-of-Care Testing (POCT) products at Booth Z1.H50. These products include:

  • Dry Chemiluminescence Immunoassay System (Dry CLIA)
  • Immunofluorescence System (FIA)
  • Dry Biochemistry System
  • Colloidal Gold Rapid Tests

The company’s participation aims to provide healthcare professionals, medical device distributors, and patients in the Middle East, Africa, and Europe with fast, reliable, and cost-effective in-vitro diagnostic solutions that enhance healthcare outcomes.

Anbio’s Featured Products at Medlab Middle East:

  • Dry Chemiluminescence Immunoassay System

The innovative dry chemiluminescence immunoassay system utilizes lyophilized reagents to enhance stability, reduce liquid reagent volume, and improve temperature resistance for room-temperature storage and transport. Compatible with nearly 70 reagents, it covers applications like coagulation, thrombosis, cancer markers, and hormone testing, ensuring reliable results across various clinical settings.

  • Immunofluorescence System

Ideal for rapid and precise detection, this immunofluorescence system is a powerful tool for Point-of-Care Testing (POCT). It supports 85 test parameters and is equipped with a built-in battery, allowing up to 8 hours of continuous testing without an external power source. Its versatility makes it suitable for various environments, including laboratories, ambulances, and pharmacies, ensuring reliable diagnostics wherever needed.

  • Dry Biochemistry System

The innovative dry biochemistry system ensures simplicity, efficiency, and reliability in various tests, particularly in emergency settings. It utilizes dry reagent strips, with one strip dedicated to each patient, and supports whole blood testing for most assays. The reagents can be stored and transported at room temperature. Offering quick and accurate biochemistry quantification, results are available in as little as 40 seconds, making it the ideal solution for fast-paced environments.

  • Colloidal Gold Rapid Tests

These tests provide a quick, easy-to-read, and reliable solution for detecting a variety of infections and conditions, offering fast results for better decision-making in patient care. With a wide range of available reagents, the system covers nearly 100 different test items, making it a cost-effective choice, particularly for large-scale screening.

About Medlab Middle East

Medlab Middle East is the region’s premier event for laboratory and medical professionals, providing access to a vast array of the latest innovations in diagnostics, laboratory management, and medical technology. With thousands of visitors and exhibitors from around the world, it serves as a vital platform for networking, collaboration, and learning about emerging trends in healthcare diagnostics.

Anbio Biotechnology’s innovative solutions at Medlab Middle East will demonstrate its commitment to advancing the future of diagnostic technology and improving healthcare delivery worldwide.

Visit us at Booth Z1.H50 at Medlab Middle East to learn more about our products and how they can transform your healthcare practices.